Phase 3 Clinical Trials With Primary Completion Dates in July 2025
This is a list of Phase 3 trials with primary completion dates in July 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | 2025-07-01 | Phase 3 | NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
| IOBT | IO Biotech, Inc. | 2025-07-01 | Phase 3 | NCT05155254 | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) |
| MEDP | Medpace Holdings, Inc. | 2025-07-01 | Phase 3 | NCT03073967 | Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects |
| OBIMF | ONDINE BIOMEDICAL INC | 2025-07-01 | Phase 3 | NCT06702878 | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections |
| VNDA | Vanda Pharmaceuticals Inc. | 2025-07-01 | Phase 3 | NCT05361707 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances |